Macrogen, Inc.

KOSDAQ:A038290 Stock Report

Market Cap: ₩152.9b

Macrogen Past Earnings Performance

Past criteria checks 1/6

Macrogen's earnings have been declining at an average annual rate of -6%, while the Life Sciences industry saw earnings declining at 4.1% annually. Revenues have been growing at an average rate of 8% per year. Macrogen's return on equity is 1.3%, and it has net margins of 1.9%.

Key information

-6.04%

Earnings growth rate

-6.48%

EPS growth rate

Life Sciences Industry Growth53.72%
Revenue growth rate7.99%
Return on equity1.28%
Net Margin1.91%
Last Earnings Update31 Mar 2026

Recent past performance updates

Analysis Article • Apr 03

There May Be Underlying Issues With The Quality Of Macrogen's (KOSDAQ:038290) Earnings

Macrogen, Inc. ( KOSDAQ:038290 ) announced strong profits, but the stock was stagnant. We did some digging, and we...
Analysis Article • Apr 02

Macrogen's (KOSDAQ:038290) Sluggish Earnings Might Be Just The Beginning Of Its Problems

The subdued market reaction suggests that Macrogen, Inc.'s ( KOSDAQ:038290 ) recent earnings didn't contain any...

Recent updates

Analysis Article • Apr 03

There May Be Underlying Issues With The Quality Of Macrogen's (KOSDAQ:038290) Earnings

Macrogen, Inc. ( KOSDAQ:038290 ) announced strong profits, but the stock was stagnant. We did some digging, and we...
Analysis Article • Dec 22

Fewer Investors Than Expected Jumping On Macrogen, Inc. (KOSDAQ:038290)

You may think that with a price-to-sales (or "P/S") ratio of 1.1x Macrogen, Inc. ( KOSDAQ:038290 ) is definitely a...
Analysis Article • Nov 09

Macrogen's (KOSDAQ:038290) Dividend Will Be ₩300.00

Macrogen, Inc. ( KOSDAQ:038290 ) has announced that it will pay a dividend of ₩300.00 per share on the 23rd of April...
Analysis Article • Mar 19

Calculating The Intrinsic Value Of Macrogen, Inc. (KOSDAQ:038290)

Key Insights The projected fair value for Macrogen is ₩15,809 based on 2 Stage Free Cash Flow to Equity Current share...
Analysis Article • Nov 13

Macrogen, Inc.'s (KOSDAQ:038290) Low P/S No Reason For Excitement

Macrogen, Inc.'s ( KOSDAQ:038290 ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a strong buy right...
Analysis Article • Jul 24

Macrogen, Inc.'s (KOSDAQ:038290) Revenues Are Not Doing Enough For Some Investors

Macrogen, Inc.'s ( KOSDAQ:038290 ) price-to-sales (or "P/S") ratio of 1.8x might make it look like a strong buy right...
Analysis Article • Apr 02

Macrogen's (KOSDAQ:038290) Sluggish Earnings Might Be Just The Beginning Of Its Problems

The subdued market reaction suggests that Macrogen, Inc.'s ( KOSDAQ:038290 ) recent earnings didn't contain any...
Analysis Article • Mar 03

Macrogen (KOSDAQ:038290) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Jan 09

Reflecting on Macrogen's (KOSDAQ:038290) Share Price Returns Over The Last Three Years

For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you...

Revenue & Expenses Breakdown

How Macrogen makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A038290 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 26199,5993,81259,5284,117
31 Dec 25195,2682,03059,3904,117
30 Sep 25179,980-70057,1433,838
30 Jun 25163,919-6,33953,6743,838
31 Mar 25145,097-7,76348,1153,838
31 Dec 24135,777-7,60344,7923,838
30 Sep 24131,729-21,73044,5534,546
30 Jun 24131,018-20,52643,9364,546
31 Mar 24131,009-20,39543,1984,546
31 Dec 23132,803-16,81440,7984,546
30 Sep 23133,923-22,28640,9774,267
30 Jun 23137,180-18,77841,3514,267
31 Mar 23136,765-20,89240,5634,267
31 Dec 22138,617-22,25340,0894,267
30 Sep 22137,8502,25741,5234,101
30 Jun 22130,77587237,4144,101
31 Mar 22130,2684,21234,8874,101
31 Dec 21129,1751,11232,6334,101
30 Sep 21125,233-12,32127,4176,244
30 Jun 21123,9621,29926,0966,244
31 Mar 21118,03721325,6536,244
31 Dec 20112,6034,26726,0226,244
30 Sep 2095,78719,62721,9336,183
30 Jun 2098,4834,34123,9536,183
31 Mar 20101,85210,52723,5966,183
31 Dec 19102,81517,89223,4256,183
30 Sep 19120,20812,05926,8106,679
30 Jun 19115,15012,48825,8086,679
31 Mar 19115,6399,10426,3696,679
31 Dec 18112,8312,64525,3416,679
30 Sep 18108,57512,55026,5925,188
30 Jun 18107,95913,22824,9145,188
31 Mar 18104,46214,17324,4575,188
31 Dec 17101,7939,52923,6205,188
30 Sep 1798,4721,66123,1164,930
30 Jun 1794,772-55821,6624,930
31 Mar 1792,395620,8364,930
31 Dec 1691,1134,30120,0814,930
30 Sep 1688,2077,04917,6914,178
30 Jun 1690,66311,89517,8774,178
31 Mar 1687,03011,50816,7774,178
31 Dec 1579,53410,17216,5224,178
30 Sep 1573,9264,74618,4823,385
30 Jun 1563,1162,81217,1523,385

Quality Earnings: A038290 has a large one-off gain of ₩1.3B impacting its last 12 months of financial results to 31st March, 2026.

Growing Profit Margin: A038290 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A038290's earnings have declined by 6% per year over the past 5 years.

Accelerating Growth: A038290 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A038290 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-29.5%).

Return on Equity

High ROE: A038290's Return on Equity (1.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 04:35
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Macrogen, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Song-hyup HanDaishin Securities Co. Ltd.
Sang-Hun LeeiM Securities
Jaehoon ChoiKorea Investment & Securities Co., Ltd.